x

Posted 19 May, 2022

Y-mAbs Therapeutics, Inc. appointed Thomas Gad as new CEO

Nasdaq:YMAB appointed new Chief Executive Officer Thomas Gad in a 8-K filed on 19 May, 2022.


  On April 22, 2022, the Board of Directors (the "Board") of Y-mAbs Therapeutics, Inc. (the "Company), appointed Thomas Gad, the Company's President and Head of Business Development & Strategy, to serve as the Company's Interim Chief Executive Officer until a new Chief Executive Officer could be engaged.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Y-mAbs Therapeutics, Inc.
Health Care/Life Sciences • Pharmaceuticals
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Market Cap
$759M
View Company Details
Y-mAbs Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On April 22, 2022, the Board of Directors (the "Board") of Y-mAbs Therapeutics, Inc. (the "Company), appointed Thomas Gad, the Company's President and Head of Business Development & Strategy, to serve as the Company's Interim Chief Executive Officer until a new Chief Executive Officer could be engaged. In consideration therefore, on May 18, 2022, the Board temporarily increased Mr. Gad's base salary by a gross monthly amount of $10,000 calculated from April 22, 2022, until such date as a new permanent Chief Executive Officer commences his or her employment with the Company.


In connection therewith and as additional compensation therefore, on May 18, 2022, Mr. Gad also received a grant of 60,000 options (the "Options"), all of which represent stock options to purchase (1) one share of the Company's common stock, par value $0.0001 per share (the "Common Stock"), under the Company's 2018 Equity Incentive Plan, at an exercise price equal to $9.52 per share, the closing sale price of the Company's Common Stock on the NASDAQ Global Select Market on May 18, 2022, The Options have the Company's customary four (4) year vesting period with 25% of the shares vesting on the anniversary of the grant date and, thereafter, as to 2.0833% of the shares in equal monthly installments through the fourth anniversary of the grant date. The Options have a ten (10) year term.


The information furnished pursuant to Item 5.02 on this Form 8-K, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.